• It’s about time…

    1…to take allergic rhinitis seriously.

  • It’s about time…

    2…to treat uncontrolled allergic rhinitis with a dual action formulation in a single device.3

  • It’s about time…

    3…to offer rapid symptom relief in 5 minutes with Dymista®.4

  • It’s about time…

    4…to get allergic rhinitis under control all year round - Dymista® is suitable for long term use.5,6

  • It’s about time…

    5…to follow national and international guidelines on when to use Dymista®.1,2,7,8


A next step for nasal and ocular symptom control9

This online resource is designed to help healthcare professionals manage their patients with seasonal or perennial allergic rhinitis, who may benefit from Dymista® after monotherapy treatment has failed to control their symptoms.

Dymista® is the only combination of an intranasal corticosteroid (INS) and an intranasal antihistamine (INAH) available in a single device.6

Dymista® is clinically proven to relieve the symptoms of moderate to severe allergic rhinitis in head to head studies involving more than 4,600 patients.5,10,11

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.6


  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.
  • Scottish Medicine Consortium (SMC). Available at: https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2018.
  • Derendorf H, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012; 74(1): 125-133.
  • Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber.
    J Allergy Clin Immunol Pract. 2018; 6(5): 1726-1732.
  • Price D, et al. MP29-02 a novel intranasal therapy for the treatment of chronic rhinitis: safety data from a 12 month-trial. Presented at EEAACI, Geneva, 16-20 June 2013.
  • Dymista® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450. Last accessed: November 2018.
  • Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-958.
  • Lipworth B, et al. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27(1): 3.
  • Meltzer E, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4): 369-377.
  • Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5):
  • Hampel FC, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105(2): 168-173.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?


hcp popup title

Mylan Connects is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Mylan Connects today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.